ERBB2 and breast carcinoma: In this study, when the subgroups were examined, breast cancer-specific survival was found to be significantly shorter in the hormone receptor (HR)-positive and human epidermal growth factor receptor-2 (HER2)-negative groups and no significant difference was found in the triple-negative, HER2-positive and hormone-negative groups [18].